NeuroMex delivers 83.5% accuracy in identifying early-stage Alzheimer’s without traditional cognitive tests, enabling rapid, scalable preventive screening. With the device now entering the partnering phase, it is poised to become a standard component of annual health examinations, opening significant revenue streams and strategic partnership opportunities in healthcare and pharmaceuticals.

«NeuroMex transforms early detection, allowing timely interventions and optimized resource use in healthcare,» said Jenny Nisser, Managing Director of saniva diagnostics GmbH. Oliver R. Baumann, CEO of Xlife Sciences AG added that «this positions Xlife Sciences at the forefront of a multi-billion-dollar market for neurodegenerative diagnostics and preventative care.»

By combining breakthrough science, regulatory approval, and clinical validation, Xlife Sciences is uniquely positioned to drive adoption, accelerate partnerships, and deliver meaningful impact for patients, healthcare systems, and investors.

Financial calendar